![肿瘤药物治疗方案及综合评价](https://wfqqreader-1252317822.image.myqcloud.com/cover/13/43604013/b_43604013.jpg)
复发转移头颈鳞癌的化疗方案
方案Ⅰ:顺铂/卡铂+氟尿嘧啶+西妥昔单抗
![](https://epubservercos.yuewen.com/B8A9D8/22919013101368106/epubprivate/OEBPS/Images/T21_221_1406_1959_2023_147070.jpg?sign=1738810906-seu6Dmh5vdfcZuQTSI4tlpiTW21wgPVs-0-b303c0eda0a358c3a9ded03415b6dccb)
方案评价
![](https://epubservercos.yuewen.com/B8A9D8/22919013101368106/epubprivate/OEBPS/Images/T21_236_2114_1969_2775_147071.jpg?sign=1738810906-zyT02ZkcTsTeflNgHFSqIQ4WUIcSbPRX-0-031c941b7c0596b1d2312bee3c76de3c)
续表
![](https://epubservercos.yuewen.com/B8A9D8/22919013101368106/epubprivate/OEBPS/Images/T22_297_336_2028_2310_147072.jpg?sign=1738810906-73rqNmXxhsNy5ZFe5fcg9w8BdTUyZQpi-0-cf00a3c9f308e567129dee36ea739cb6)
点评
FP/CP联合西妥昔单抗可作为复发转移性头颈部鳞癌的一线治疗方案,证据来源于Ⅲ期随机对照研究NCT00122360,适用于大于18岁、Karnofsky评分大于70分、器官功能良好、具有可测量病灶的复发转移头颈部鳞状细胞癌患者。
(吴 昕 张琼文)
参考文献
[1] VERMORKEN JB,MESIA R,RIVERA F,et al.Platinum-based chemotherapy plus cetuximab in head and neck cancer.N Engl J Med,2008,359:1116-1127.
方案Ⅱ 顺铂+紫杉醇/顺铂+氟尿嘧啶
![](https://epubservercos.yuewen.com/B8A9D8/22919013101368106/epubprivate/OEBPS/Images/T23_236_752_1974_1108_147075.jpg?sign=1738810906-qzZgrpExUeztBhM39BaRtrK7QVTvtuko-0-e6082ba14e5afa207fbf8c2412769f14)
方案评价
![](https://epubservercos.yuewen.com/B8A9D8/22919013101368106/epubprivate/OEBPS/Images/T23_228_1187_1969_2841_76616.jpg?sign=1738810906-LqqxGrUedfJz88hYALXIk5Or1l1WQjIS-0-7d2916cd7f6b262a77cc066393632f1c)
续表
![](https://epubservercos.yuewen.com/B8A9D8/22919013101368106/epubprivate/OEBPS/Images/T24_292_339_2040_1214_146907.jpg?sign=1738810906-kruwLWg7gKs04rTYhj9sLdjbXGNILG3G-0-b3bf103cf79d40b969fc29fdb97078d9)
点评
CP方案是复发转移头颈鳞癌的备选方案,证据来源于Ⅲ期随机对照临床研究,适用于年龄>18岁,ECOG PS评分0~1,无颅内转移的复发转移头颈鳞癌患者,既往化疗史满足:紫杉醇/氟尿嘧啶>12个月,顺铂>6个月。CP方案与CF方案的总生存与反应率无显著性差异,CF方案的近期疗效略好而不良事件发生率较高,但无统计学差异。此项研究成果为复发转移头颈部鳞癌的化疗提供了新的治疗选择。
(吴 昕 张琼文)
参考文献
[1] GIBSON MK,LI Y,MURPHY B,et al.Randomized phase Ⅲ evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer(E1395):An Intergroup Trial of the Eastern Cooperative Oncology Group.J Clin Oncol,2005,23:3562-3567.
方案Ⅲ 顺铂+西妥昔单抗
![](https://epubservercos.yuewen.com/B8A9D8/22919013101368106/epubprivate/OEBPS/Images/T24_292_2337_2035_2834_147077.jpg?sign=1738810906-Y4LOD9fKiXfGLDhOTMSUSBXuN9PLujNS-0-ed9294260e9e8190f292d9aea9860e3f)
方案评价
![](https://epubservercos.yuewen.com/B8A9D8/22919013101368106/epubprivate/OEBPS/Images/T25_236_344_1959_2785_147078.jpg?sign=1738810906-sL8921j2i9mu5iIhOafFVilxhvzgT9Bi-0-8bfae8ceec95be2b4c3e1eff98703b94)
点评
西妥昔单抗联合顺铂是治疗复发转移性头颈部鳞癌的优选方案,证据来源于Ⅲ期随机对照临床研究。适用于>18岁、ECOGPS评分0~1分、具有可测量病灶的、器官功能良好的、3个月内无化疗史的复发转移性头颈部鳞状细胞癌。
(吴 昕 张琼文)
参考文献
[1] BURTNESS B,GOLDWASSER MA,FLOOD W,et al.Phase Ⅲ randomized trial of cisplatin plus placebo versus cisplatin plus cetuximab in metastatic/recurrent head and neck cancer:An Eastern Cooperative Oncology Group Study.J Clin Oncol,2005,23:8646-8654.
方案Ⅳ 吉非替尼
![](https://epubservercos.yuewen.com/B8A9D8/22919013101368106/epubprivate/OEBPS/Images/T26_292_1261_2035_1541_147296.jpg?sign=1738810906-kX1eBu8wn6SbXH9iwDBtaCoMuf5oiRRg-0-11991eae420eebb6745ed3e6afde345f)
方案评价
![](https://epubservercos.yuewen.com/B8A9D8/22919013101368106/epubprivate/OEBPS/Images/T26_290_1622_2043_2780_147297.jpg?sign=1738810906-QNE0EWYL390bRhCtKRzXFicc9T9ASSsm-0-7a0d13c32c026da5556a295de0b28d60)
续表
![](https://epubservercos.yuewen.com/B8A9D8/22919013101368106/epubprivate/OEBPS/Images/T27_228_336_1961_2190_147298.jpg?sign=1738810906-bLnB5MmeadwA16RJIRjk7Q8GumEbKRfG-0-c5320fc57d8daaea3de57b009d0d58c5)
点评
吉西他滨方案在复发转移性头颈部鳞癌中不优于甲氨蝶呤方案。证据来源于Ⅲ期随机对照研究,适用于放疗后、对化疗史没有特别限制的复发转移性头颈部鳞癌患者。
(吴 昕 张琼文)
参考文献
[1] STEWART JS,COHEN EE,LICITRA L,et al.Phase Ⅲ study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck.J Clin Oncol,2009,27:1864-1871.